Safety and Effectiveness of Molnupiravir in Japanese Patients with COVID-19: Final Report of Post-marketing Surveillance in Japan

Shohei Shinozaki, Asuka Watanabe, Masahiro Kimata, Makoto Miyazaki, Shinichiroh Maekawa

Open source

DOI
10.1007/s40121-023-00915-w
Published
2024-01
Container
Infectious Diseases and Therapy
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s40121-023-00915-w,
  title = {Safety and Effectiveness of Molnupiravir in Japanese Patients with COVID-19: Final Report of Post-marketing Surveillance in Japan},
  author = {Shohei Shinozaki and Asuka Watanabe and Masahiro Kimata and Makoto Miyazaki and Shinichiroh Maekawa},
  year = {2024},
  journal = {Infectious Diseases and Therapy},
  doi = {10.1007/s40121-023-00915-w},
  url = {https://doi.org/10.1007/s40121-023-00915-w}
}

RIS

TY  - JOUR
TI  - Safety and Effectiveness of Molnupiravir in Japanese Patients with COVID-19: Final Report of Post-marketing Surveillance in Japan
AU  - Shohei Shinozaki
AU  - Asuka Watanabe
AU  - Masahiro Kimata
AU  - Makoto Miyazaki
AU  - Shinichiroh Maekawa
PY  - 2024
JO  - Infectious Diseases and Therapy
DO  - 10.1007/s40121-023-00915-w
UR  - https://doi.org/10.1007/s40121-023-00915-w
ER  - 

APA

Shinozaki, S., Watanabe, A., Kimata, M., Miyazaki, M., & Maekawa, S. (2024). Safety and Effectiveness of Molnupiravir in Japanese Patients with COVID-19: Final Report of Post-marketing Surveillance in Japan. Infectious Diseases and Therapy. https://doi.org/10.1007/s40121-023-00915-w

Source records